SUNNYVALE, Calif., Dec. 5 /PRNewswire-FirstCall/ -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Christopher R. Barys to the position of Senior Vice President, Sales. Mr. Barys comes to FlowCardia with over 16 years of experience in Medical Devices, 12 years of which have been in the interventional endovascular products field.
Most recently, Mr. Barys served as Vice President of Sales and Marketing for the Peripheral Vascular Systems business for Edwards Lifesciences where he had broad responsibility for this rapidly growing business segment. Previously, Mr. Barys held Senior Sales and Marketing positions at Johnson & Johnson's Cordis Division, Boston Scientific and U.S. Surgical.
"We are tremendously pleased that Chris will be joining FlowCardia at this important time for the Company. His extensive experience in leading large national sales forces will be very valuable as FlowCardia initiates the immediate launch of its CROSSER System to Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons," said Wick Goodspeed, President and CEO of FlowCardia. "I am confident that Chris will be a substantial contributor to our commercialization success in 2008 and the coming years."
"This is an exciting time to be joining FlowCardia. I look forward to working closely with Wick and the rest of the management team at the Company," said Mr. Barys. "FlowCardia is on the cusp of rapid growth and I am enthusiastic about the opportunity to introduce a significantly less invasive therapeutic option for coronary and peripheral CTO patients."
FlowCardia, Inc. is a privately held medical device company established
in 2002 to design and manufacture safe and effective, endovascular CTO
recanalization systems. Additional information is available on the
Company's Web Site at http://www.flowcardia.com.
CONTACT: Mark Page
Sr. Director, Marketing
|SOURCE FlowCardia, Inc.|
Copyright©2007 PR Newswire.
All rights reserved